The indications and methods for and volumes of nuclear cardiology procedures differ among countries, and each country has specific nuclear cardiology characteristics. Nuclear cardiology practice in Japan has the following specific characteristics: 1) stress myocardial perfusion imaging is severely underused; 2) thallium-201 (  201 Tl) (ASNC2017), which provided us with a precious opportunity to discuss issues related to nuclear cardiology with nuclear cardiologists from all over the world. Specifically, we had the opportunity to summarize the specific characteristics of nuclear cardiology practice in Japan.
accounts for roughly 20% of the public radiation burden around the world (1) . However, the contribution of medical radiation is much larger in developed countries, and each country has its own specific characteristics.
The US is a major user of nuclear cardiology. Thus, approximately 10% of the public radiation burden in the US is caused by nuclear cardiology procedures alone, and roughly 50% is from medical procedures (2) . In Japan, medical radiation is more important because roughly two thirds of the public radiation burden is due to medical radiation, which is a much larger proportion than is seen in the US (3) . However, the contribution of nuclear cardiology to the public radiation burden is quite small in Japan. In fact, the sum of all nuclear medicine procedures (not only those related to cardiology) only contributes about 1% to the public radiation burden (3).
The major reason for this difference is the heavy underusage of nuclear cardiology procedures in Japan.
Information about the number of imaging examinations performed each year in Japan is presented in Fig. 1 (data from JROAD: The Japanese Registry of All Cardiac and Vascular Diseases) (4) . Briefly, the number of MPI procedures carried out each year is much lower than the number of coronary angiography scans and even lower than that of coronary computed tomography angiography (CTA) scans. As shown in Fig. 1 , the number of cardiac CTA examinations conducted in Japan is very high and is rapidly increasing. On the other hand, the number of stress MPI procedures performed in Japan has declined slightly. The annual number of pharmacological stress MPI procedures has increased slightly; however, the increase was not enough to compensate for the reduction in the number of exercise MPI procedures. In addition, the number of cardiac positron emission tomography (PET) scans has tended to increase, but it is still so low as to be negligible compared with the frequencies of other examinations.
The incredibly high and increasing usage of cardiac CT scans is probably due to their easy availability in Japan. As is well known, the number of CT scanners per population is higher in Japan than anywhere else in the world (there were 101.28 scanners per million population in 2011). In fact, the figure for Japan is almost twice as high as that for the country with the second highest number of CT scanners per population (Australia: 59.61 scanners per million population in 2015) (5) .
In addition, the total number of CT scanners in Japan is almost equal to the number of Walmart stores around the world (Fig. 2) .
These statistics indicate that in Japan current practice regarding ischemic heart disease centers around percutaneous coronary interventions/CTA, and so patients with ischemic heart disease might be being treated without appropriate noninvasive examinations of physiological ischemia, such as stress MPI scans.
Thus, Japanese nuclear cardiologists are heavily underusing stress MPI. However, recently the importance of the physiology of myocardial perfusion has begun to be recognized by many cardiac interventionalists in Japan.
Numerous studies have indicated that physiological ischemia, which can be assessed based on the fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR), is an important determinant of prognosis in ischemic heart disease and that information about physiological ischemia can aid decisionmaking in such cases (6) (7) (8) (9) . These findings have resulted in a strong trend towards the measurement of the FFR and iFR during "invasive" coronary angiography. This in turn seems to have encouraged the use of MPI, which has made many interventionalists realize that stress MPI is the optimal method for "non-invasively" assessing the physiology of myocardial perfusion. The Japanese Society of Nuclear Cardiology (JSNC) is working on facilitating greater MPI usage in Japan.
The JSNC considers that young cardiologists who are not yet familiar with nuclear cardiology are the most important targets of programs for facilitating nuclear cardiology. Therefore, we are publishing a nuclear cardiology textbook, which covers everything from basic aspects of nuclear cardiology to Kudo Present Status of Nuclear Cardiology in Japan Ann Nucl Cardiol 2018；4（1） ：142-148 -143 - practical protocols. In addition to information about perfusion imaging, it also provides information about metabolic and sympathetic imaging, which are mentioned later in this review.
This textbook is frequently revised, and the present version is more than 120 pages long. We are also hosting local workshops twice a year in eight areas of Japan to help young cardiologists understand the basics of nuclear cardiology.
Tl usage and medical radiation
Around the world, 201 Tl has been replaced with 99m Tc-labeled agents are provided in syringe form. The majority of MPI studies are performed using these syringebased tracers. In Japan, syringe-based 99m Tc-labeled MPI agents are usually used. Thus, dose estimates were calculated based on the assumption that a small syringe (296 MBq of tetrofosmin or 370 MBq of MIBI) would be injected at 9:00 for stress imaging, and a large syringe (740 MBq of either tracer) would be injected at 13:00 for rest imaging without any dose modification.
< 9 mSv, which is the target dose recommended by the American Society of Nuclear Cardiology in 2010 (13) . These findings indicate that the radiation burden placed on patients by nuclear cardiology procedures in Japan is not excessive. A typical stress MPI procedure and the estimated effective doses for each protocol are described in Fig. 3 and Table 1, respectively (14, 15) .
However, this is only due to a fortunate coincidence. The rules for the delivery of and reference doses for long half-life tracers were changed in April 2016, and the abovementioned survey was performed after the new rules came into force. We do not have any objective data that were collected before April 2016; thus, we cannot calculate the radiation doses adminis- technologists. Thus, the very high workload of Japanese cardiologists often makes it hard to find a doctor to perform a second radiopharmaceutical injection.
As the reasons given for the continued use of 201 Tl represent practical rather than scientific issues, it will be very hard to change this situation rapidly. However, to improve this situation, the JSNC created a working group for "optimizing the radiation burden associated with nuclear cardiology procedures". We are planning to distribute the first version of our guidelines in 2018. It is considered that switching from 201 Tl to 99m Tc would cut the radiation burden by almost 50%
and result in better image quality (mainly due to an improved signal to noise ratio). In our guidelines, we are planning to compare the radiation burdens associated with A multicenter cohort study evaluating the utility of BMIPP imaging for estimating cardiac mortality among HD patients (the B-SAFE trial) revealed that clear risk stratification can be achieved using the BMIPP scoring system (24) . In this cohort study, cardiac mortality, including sudden death, accounted for roughly one third of all-cause mortality, and 16% of deaths were classified as cerebrovascular or other vascular deaths.
The remaining deaths were non-cardiac/vascular deaths. In the B-SAFE study, patients with low (<4) and high (>8) BMIPP scores exhibited good (95.7%) and very poor (78.8%) 3-year Kudo Present Status of Nuclear Cardiology in Japan Ann Nucl Cardiol 2018；4（1） ：142-148 -145 -cardiac-related death-free survival, respectively. Interestingly, such clear risk stratification was only observed for cardiacrelated mortality.
However, considering the huge number of HD patients being treated in Japan, it would still be unrealistic to perform BMIPP imaging regularly in all HD patients. When CKD patients are included as well, the number of potential examinations is even greater. Thus, we should consider "triaging" such patients in order to identify those who would benefit most from BMIPP imaging.
A study by Nakata et al. provided a good roadmap for selecting appropriate CKD/HD patients for BMIPP imaging (19) . They combined electrocardiography (ECG), blood tests, and BMIPP imaging and selected an abnormal Q wave on ECG, a C-reactive protein (CRP) level of >2.38, and a BMIPP score of >16 as prognostic markers for such patients. They found that the prognosis of the patients who displayed only one of the three markers was similar to that of the patients who exhibited none of the three markers. On the other hand, the patients who possessed two or three of these markers had critically poor prognoses. These findings indicate that it is possible to select appropriate patients for BMIPP imaging with simple and inexpensive ECG and blood sampling. BMIPP imaging should only be performed in patients who exhibit abnormal Q waves or CRP levels of >2.38.
One of the major concerns about the usage of BMIPP is the additional radiation burden it places on the patient. The radiation burden produced by a standard BMIPP procedure (Table 1) Unlike for BMIPP, MIBG usage is mainly recommended for diagnosing heart failure and arrhythmic disease, rather than for ischemic heart disease. Specifically, it is recommended (class I, level B evidence) that MIBG should be used to evaluate disease severity/prognosis in patients with heart failure.
However, over the past few years the usage of MIBG in Japan has changed. Recently, MIBG has been mainly used in neurology, rather than in cardiology, in Japan.
Nakajima et al. reported that in 2012, 62% of MIBG-based procedures conducted in Japan were performed to obtain a neurological diagnosis (25) . This phenomenon arose due to the Kudo Present Status of Nuclear Cardiology in Japan Ann Nucl Cardiol 2018；4（1） ：142-148 -146 - According to a patient survey published in 2014, there were 163,000 PD patients in Japan. This survey indicated that the number of PD patients is increasing and is becoming a huge problem for society (27) . Among neurological diseases, DLB is the second most common cause of dementia (the most common is Alzheimer' s disease). Differential diagnosis is important in such cases because there are many diseases that present with similar symptoms to PD (Parkinson syndromes, such as progressive supranuclear palsy, multiple systemic atrophy, etc.) and DLB (other types of dementia, such as Alzheimer's disease, argyrophilic grain dementia, etc.). In PD and DLB, markedly decreased myocardial uptake of MIBG is seen (28) . This phenomenon is specific to PD/DLB and is not found in other degenerative diseases that cause Parkinson syndromes (non-PD PS). This indicates that MIBG can be used to clearly distinguish between PD and non-PD PS.
According to these important findings, MIBG is classified as an "indicative" biomarker for the diagnosis of PD in the 4th consensus report of the DLB consortium (29) .
As is the case for BMIPP, the usage of MIBG also raises questions regarding the radiation burden placed on patients.
The estimated radiation dose delivered during the standard MIBG procedure (Fig. 4) is roughly 1.5 mSv/procedure (0.013 mSv/MBq, 111 MBq/procedure). Like BMIPP imaging, MIBG imaging is also only performed in selected patients.
Thus, we do not consider that the associated radiation burden is too high. However, considering the large number of PD patients, we should carefully choose patients who would receive clear benefits from the use of this tracer. Thus, MIBG imaging should not be used as a screening test for PD.
Conclusion
There are many differences between the nuclear cardiology procedures performed in Japan and those conducted in other countries. In some respects, Japan is behind the global standard and must follow the lead of other countries. However, in other areas Japanese nuclear cardiologists can pave the way for other countries.
